Clinical Trials
26 trialsA Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute
KEYVIBE-005
Merck Sharp & Dohme LLC
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
OHSU Knight Cancer Institute
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PEACH
Yonsei University
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatic Artery Infusion Chemotherapy for Unresectable Hepatocelluar Carcinoma Who Failed to Systemic Therapy
Shanghai Zhongshan Hospital
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
The University of Hong Kong
Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
Sun Yat-sen University
PACOX
Bio-Cancer Treatment International Limited
NRR
UNC Lineberger Comprehensive Cancer Center
Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers
National Cancer Institute (NCI)
Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil
Sun Yat-sen University
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC
Sun Yat-sen University
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
Massachusetts General Hospital
Oxaliplatin in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
Sanofi
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Oxaliplatin in Unresectable Hepatocellular Carcinoma
Sanofi
SECOX
The University of Hong Kong
Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
Rigshospitalet, Denmark